Dr. Byers is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Lauren (Averett) Byers, MD is a Professor and Thoracic Section Chief in the Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center. Dr. Byers completed her B.A. degree in Molecular Biology at Princeton University in 1998, her M.D. degree at Baylor College of Medicine in 2003, and M.S. degree in Patient-Based Research at the University of Texas Graduate School of Biomedical Sciences in 2009. Following her Clinical Residency in Internal Medicine at Johns Hopkins Hospital, Dr. Byers joined MD Anderson Cancer Center in 2006 as a Clinical Fellow in Medical Oncology and later as an Advanced Scholar Fellow.
As a physician-scientist, Dr. Byers’ research focuses on high-throughput molecular profiling to identify new therapeutic targets, predictive biomarkers, and mechanisms of resistance, especially in the area of Small Cell Lung Cancer (SCLC).
Education & Training
- University of Texas Health Science Center at HoustonFellowship, Medical Oncology, 2006 - 2009
- Baylor College of MedicineClass of 2003
Certifications & Licensure
- FL State Medical License 2021 - Present
- AZ State Medical License 2023 - 2026
- TX State Medical License 2006 - 2026
- AL State Medical License 2023 - 2025
- MS State Medical License 2023 - 2025
- OK State Medical License 2020 - 2025
- TN State Medical License 2023 - 2025
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Start of enrollment: 2011 Jan 03
- Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer Start of enrollment: 2012 Jun 01
- A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Start of enrollment: 2016 May 11
Publications & Presentations
PubMed
- Anti-tumor activity and biomarker analysis for TROP2-antibody drug conjugate Datopotamab deruxtecan in patient-derived breast cancer xenograft models.Funda Meric-Bernstam, Erkan Yuca, Kurt W Evans, Ming Zhao, Takanori Maejima
Clinical Cancer Research. 2024-11-25 - Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms.Alejandra G Serrano, Pedro Rocha, Cibelle Freitas Lima, Allison Stewart, Bingnan Zhang
NPJ Precision Oncology. 2024-11-19 - Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929.Nagla Abdel Karim, Jieling Miao, Karen L Reckamp, Carl M Gay, Lauren A Byers
Journal of Thoracic Oncology. 2024-11-04
Journal Articles
- Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies Across Platinum-Resistant CancersFaye M Johnson, John V Heymach, Lauren Averett Byers, Clinical Cancer Research
Press Mentions
- Durvalumab Wins FDA Approval in Limited-Stage SCLCDecember 5th, 2024
- How Are Targeted Therapies Used in Lung Cancer Treatment?July 30th, 2024
- Limited-Stage SCLC Gets a New Standard of Care with Consolidation DurvalumabJune 3rd, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: